UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 8 von 1326
Datensatz exportieren als...
BibTeX
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program
American journal of hematology, 2015-05, Vol.90 (5), p.429-433
García‐Gutiérrez, Valentín
Martinez‐Trillos, Alejandra
Lopez Lorenzo, Jose Luis
Bautista, Guiomar
Martin Mateos, Maria Luisa
Alvarez‐Larrán, Alberto
Iglesias Pérez, Ana
Romo Collado, Andrés
Fernandez, Angeles
Portero, Angeles
Cuevas, Beatriz
Ruiz, Concepción
Romero, Esperanza
Ortega, Fernando
Mata, Isabel
Tallón, José
García Garay, Maria del Carmen
Ramirez Sánchez, María José
de las Heras, Natalia
Giraldo, Pilar
Bobillo, Sabela
Guinea, José María
Deben, Guillermo
Valencia, Sandra
Sebrango, Ana
Boqué, Concepción
Maestro, Begoña
Steegmann, Juan Luis
2015
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
García‐Gutiérrez, Valentín
Martinez‐Trillos, Alejandra
Lopez Lorenzo, Jose Luis
Bautista, Guiomar
Martin Mateos, Maria Luisa
Alvarez‐Larrán, Alberto
Iglesias Pérez, Ana
Romo Collado, Andrés
Fernandez, Angeles
Portero, Angeles
Cuevas, Beatriz
Ruiz, Concepción
Romero, Esperanza
Ortega, Fernando
Mata, Isabel
Tallón, José
García Garay, Maria del Carmen
Ramirez Sánchez, María José
de las Heras, Natalia
Giraldo, Pilar
Bobillo, Sabela
Guinea, José María
Deben, Guillermo
Valencia, Sandra
Sebrango, Ana
Boqué, Concepción
Maestro, Begoña
Steegmann, Juan Luis
Titel
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program
Ist Teil von
American journal of hematology, 2015-05, Vol.90 (5), p.429-433
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2015
Quelle
Wiley-Blackwell Journals
Beschreibungen/Notizen
The role of bosutinib as rescue treatment of Philadelphia chromosome‐positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowledge) of patients treated with bosutinib in fourth‐line, after retrospectively reviewing 30 patients in chronic phase, and pretreated with imatinib, nilotinib, and dasatinib. With a median follow up of 11.1 months, the probability to either maintain or improve their CCyR response was 56.6% (17/30) and 11 patients (36.7%) achieved or maintained their baseline MMR. In patients not having baseline CCyR, the probabilities of obtaining CCyR, MMR, and MR4.5 were 13, 11, and 14%, respectively. The probabilities of obtaining MMR and deep molecular response MR4.5 in patients with baseline CCyR were 40.0% (6/15) and 20.0% (3/15). At 20 months, progression‐free survival was 73%. Grade 3–4 hematological toxicities were more frequent in resistant than intolerant patients (45.4 vs. 0.0%). Nonhematological toxicities were also more frequent in resistant patients, being diarrhea the most conspicuous one. Bosutinib seems to be an appropriate treatment option for patients resistant or intolerant to three prior TKI's.Am. J. Hematol. 90:429–433, 2015. © 2015 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0361-8609
eISSN: 1096-8652
DOI: 10.1002/ajh.23973
Titel-ID: cdi_proquest_miscellaneous_1675872079
Format
–
Schlagworte
Adult
,
Aged
,
Aniline Compounds - therapeutic use
,
Antineoplastic Agents - therapeutic use
,
Benzamides - therapeutic use
,
Compassionate Use Trials
,
Dasatinib
,
Drug Resistance, Neoplasm
,
Female
,
Hematology
,
Humans
,
Imatinib Mesylate
,
Leukemia, Myeloid, Chronic-Phase - drug therapy
,
Leukemia, Myeloid, Chronic-Phase - enzymology
,
Leukemia, Myeloid, Chronic-Phase - mortality
,
Leukemia, Myeloid, Chronic-Phase - pathology
,
Male
,
Middle Aged
,
Nitriles - therapeutic use
,
Piperazines - therapeutic use
,
Protein Kinase Inhibitors - therapeutic use
,
Protein-Tyrosine Kinases - antagonists & inhibitors
,
Protein-Tyrosine Kinases - metabolism
,
Pyrimidines - therapeutic use
,
Quinolines - therapeutic use
,
Retrospective Studies
,
Spain
,
Survival Analysis
,
Thiazoles - therapeutic use
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX